192 related articles for article (PubMed ID: 20160726)
1. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
Neville-Webbe HL; Coleman RE; Holen I
Br J Cancer; 2010 Mar; 102(6):1010-7. PubMed ID: 20160726
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
Schech AJ; Nemieboka BE; Brodie AH
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):195-202. PubMed ID: 22659283
[TBL] [Abstract][Full Text] [Related]
3. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
4. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
6. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
[TBL] [Abstract][Full Text] [Related]
7. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Hines SL; Sloan JA; Atherton PJ; Perez EA; Dakhil SR; Johnson DB; Reddy PS; Dalton RJ; Mattar BI; Loprinzi CL
Breast; 2010 Apr; 19(2):92-6. PubMed ID: 20079640
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
10. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Aapro M
Breast; 2006 Feb; 15 Suppl 1():S30-40. PubMed ID: 16500238
[TBL] [Abstract][Full Text] [Related]
11. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
[TBL] [Abstract][Full Text] [Related]
13. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
[TBL] [Abstract][Full Text] [Related]
14. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
15. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Hines SL; Mincey B; Dentchev T; Sloan JA; Perez EA; Johnson DB; Schaefer PL; Alberts S; Liu H; Kahanic S; Mazurczak MA; Nikcevich DA; Loprinzi CL
Breast Cancer Res Treat; 2009 Oct; 117(3):603-9. PubMed ID: 19214743
[TBL] [Abstract][Full Text] [Related]
16. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth.
Liang YJ; Hao Q; Wu YZ; Wang QL; Wang JD; Hu YL
Int J Gynecol Cancer; 2009 Oct; 19(7):1248-52. PubMed ID: 19823063
[TBL] [Abstract][Full Text] [Related]
18. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
[TBL] [Abstract][Full Text] [Related]
19. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]